Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined Quadrivalent Influenza and 23-Valent Pneumococcal Vaccination in Elderly
NCT05471531Phase 4Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Nov 2021
- Primary completion
- Mar 2022
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of quadrivalent influenza vaccine and Sinovac 23-valent pneumococcal polysaccharide vaccine in influenza and Pneumococcal pneumonia (PP) (4 arms), sponsored by Sinovac Biotech Ltd. Primary endpoint: Geometric mean titer of influenza HI antibodies at 28 days. Started Nov 2021; status: completed.
02
Drugs
quadrivalent influenza vaccineSinovac 23-valent pneumococcal polysaccharide vaccine
03
Conditions
influenzaPneumococcal pneumonia (PP)
Beyond the preview
Go deeper on NCT05471531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05471531.